Medicine, Health & Food

Medicine, Health & Food

DESCRIPTION OF CLINICOPATHOLOGY PATIENTS WITH INVASIVE BREAST CARCINOMA NO SPECIAL TYPE (NST) THAT HAVE NOT BEEN AND HAS NOT BEEN EXPERIENCED LYMPHOVASCULAR IN RS. H. ADAM MALIK MEDAN IN 2018

Pages: 10  ,  Volume: 45  ,  Issue: 1 , January   2020
Received: 20 Jan 2020  ,  Published: 22 January 2020
Views: 67  ,  Download: 0

Authors

# Author Name
1 Hengky Ardian
2 Joko S Lukito
3 Soekimin

Abstract

ABSTRACT

Background: Breast carcinoma is the most common type of cancer affecting women. Breast cancer is cancer that can metastasize to other organs such as bones, liver, lungs, and brain, most of which cause this disease can not be treated. In breast cancer, LVI has become one of the factors for disease-free survival as well as overall survival.

Objective: to know the description of clinicopathology (age, grading, tumor size, the involvement of lymph nodes, and stage) patients with breast carcinoma Invasive No special type (NST) who have and have not experienced Lymphovascular Invasion.

Material and Methods: This research is a descriptive study with a cross-sectional approach of 54 NST patients. Data on the clinicopathological characteristics were obtained from the patient's medical records. Then, a slide review is conducted. The results of the data analysis are presented in the form of a frequency table.

Results: Based on age, LVI positive breast cancer was most vulnerable at the age of 35-49 years 4 people, LVI tumor size was highest at ≤5 cm in size of 3 people, LVI positive with no involvement of 5 KGB people, at LVI positive stage most at stage II that is equal to 2 people, and the most positive grade is LVI in grade 2 which is equal to 3 people.

Conclusion: LVI is one of the prognostic factors in patients with invasive breast cancer no special type (NST) and should be reported in the diagnosis of anatomic pathology

Keywords: Invasive breast cancer no special type (NST) and Lymphovascular Invasion (LVI)

 

Keywords

  • Invasive breast cancer no special type (NST) and Lymphovascular Invasion (LVI)
  • References

     

    1. Gluz O, Liodtke C, Gottschal N, Pusztai L, Nitz U, Harbeck N. Triple-negative breast cancer-current status and future direc-tions.Annals of Oncology.2009;20:1913-27.
    2. WHO. Latest global cancer data: Cancer burden rises to 18.1 million new cases and 9.6 million cancer deaths in 2018. International Agency For Research on Cancer, 2018
    3. Sun Y., Zhao, Z. Risk factors and preventions of breast cancer. International Journal of Biological Sciences. 2017; 13(11): 1387-1397. doi: 10.7150/ijbs.21635
    4. Oemiati R., Rahajeng E., Kristanto A.Y. 2011. Prevalensi Tumor dan beberapa faktor yang Mempengaruhinya di Indonesia. Bul. Penelit. Kesehat 39(4); 190 – 204.
    5. Niemiec J,  Adamczyk A, Ambicka A, Mucha-Ma?ecka A, Wysocki WM, Biesaga B et al. Prognostic role of lymphatic vessel density and lymphovascular invasion in chemotherapy-naive and chemotherapy-treated patients with invasive breast cancer, Am J Transl Res 2017;9(3):1435-1447     (6)
    6. Da?lar G., Yuksek Y.N., Gozalan A.U., Tutuncu T., Gungor Y., and Kama N.A. 2010. The Prognostic Value of Histopatological Grade in the Outcome of Patients with Invasive Breast Cancer. Turk J Med Sci 40(1); 7-15.   (8)
    7. Hoda SA. Invasive lobular carcinoma. In: Hoda SA, Brogi E, Koerner FC, Rosen P eds. Rosen’s Breast Pathology. Chapter 33. 4th ed. Philladelphia. Lippincott Williams & wilkins. 2015. p855-93  (9)
    8. Shen S., Zhong S. Correlation OfLymphovascular Invasion With Clinicopathological Factors In Invasive Breast Cancer: A Meta-Analysis. Int J ClinExp Med 2015;8(10):17789-17795  (11)
    9. Song Y., Shin S., The Role of Lymphovascular Invasion as a Prognostic Factor in Patients withLymph Node-Positive Operable Invasive Breast Cancer. J Breast Cancer 2011 September; 14(3): 198-203 http://dx.doi.org/10.4048/jbc.2011.14.3.198   (12)
    10. Kumar, P., and Clark M., 2006, Faktor Risiko Kanker Payudara karena Riwayat  Keluarga, Clinical Medicine Sixth Edition, terdapat di: http://www.studentconsult.com/content/default.cfm?ISBN=0702027634 &ID=HC009018
    11. Shen S, Wu G, Xiao G, et al. Prediction model of lymphovascular invasion based on clinicopathological factors in Chinese patients with invasive breast cancer. Medicine (Baltimore). 2018;97(43):e12973. doi:10.1097/MD.0000000000012973  (43)
    12. Stevens A, Lowe J, Scott I, editor (penyunting). Core Pathology. Edisi ke-3. United Kingdom: Elsevier; 2009. (47)
    13. Kim S, Park HK, Lim SD. ERG Immuno histochemistry as an endothelial marker for assessing lymphovascular invasion. The Korean Journal of Pathology. 2013;47:503.